neutrophil count follicular phase
Selected indexed studies
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (Lancet Oncol, 2022) [PMID:35803286]
- Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. (Blood, 2022) [PMID:35303070]
- The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. (Br J Dermatol, 2025) [PMID:39531733]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. (2022) pubmed
- Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. (2022) pubmed
- Fertility preservation by ovarian tissue cryopreservation of children in China--umbilical single-incision surgery and perioperative experience. (2025) pubmed
- Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. (2020) pubmed
- Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study. (2024) pubmed
- Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors. (2024) pubmed
- Influence of Menstrual Cycle on Leukocyte Response Following Exercise-Induced Muscle Damage. (2022) pubmed
- The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. (2025) pubmed
- Ocular manifestations of coronavirus disease 2019. (2020) pubmed
- Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. (2018) pubmed